Orbas 20: Each film-coated tablet contains Olmesartan Medoxomil BP 20 mg.
Orbas 40: Each film-coated tablet contains Olmesartan Medoxomil BP 40 mg.
Orbas (Olmesartan Medoxomil), a prodrug, is hydrolyzed to Olmesartan during absorption from the gastrointestinal tract. Orbas (Olmesartan Medoxomil) is a selective AT, subtype angiotensin II receptor antagonist. Orbas (Olmesartan Medoxomil) blocks the vasoconstrictor effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT, receptor in vascular smooth muscle. Its action is, therefore, independent of the pathways for angiotensin II synthesis.
Adult:Hypertension:
The usual starting dose of Orbas (Olmesartan Medoxomil) is 20 mg once daily. Dosing should be individualized. Depending on the blood pressure response, the dose may be increased after 2 weeks to 40 mg. Orbas (Olmesartan Medoxomil) may be administered with or without food.
No initial dosage adjustment is recommended for elderly patients, for patients with moderate to marked renal impairment (creatinine clearance < 40 mL/min) or with moderate to marked hepatic dysfunction.
If blood pressure is not controlled by Orbas (Olmesartan Medoxomil) alone, a diuretic may be added. Orbas (Olmesartan Medoxomil) may be administered with other antihypertensive agents.
Pediatric Hypertension (6 to 16 years of age):
The usual recommended starting dose of Orbas (Olmesartan Medoxomil) is 10 mg once daily for patients who weigh 20 to 35 kg. For patients requiring further reduction in blood pressure after 2 weeks of therapy, the dose may be increased to a maximum of 20 mg once daily for who weigh 35 kg.
OR, AS DIRECTED BY PHYSICIAN.
No significant drug interactions were reported in studies in which Olmesartan Medoxomil was co-administrated with digoxin or warfarin in healthy volunteers. Olmesartan Medoxomil is not metabolized by the cytochrome P450 system and has no effects on P450 enzymes; thus, interactions with drugs that inhibit, induce or are metabolized by those enzymes are not expected. The bioavailability of Olmesartan is not significantly altered by the co-administration of antacids.
Over dose:
Limited data are available in regard to over dose in humans. The most likely manifestation of over dose would be hypotension and tachycardia, bradycardia could occur from parasympathetic (Vagal) stimulation. If symptomatic hypotension occurs, supportive treatment should be initiated.
Safety and effectiveness in both pregnant women & nursing mother have not been established. So, Olmesartan should be discontinued during both of these conditions.
Keep all medicines out of reach of children. Store in a cool & dry place, protected from light.